NCT03655522

NAVX-010-Phase I Tolerability and Pharmacokinetic Study in Healthy Male Subjects

NAVX-010 - A Phase I, Double-Blind, Placebo-Controlled, Single-Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Algenis SpA · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This was a double-blind, placebo-controlled, randomized, single ascending dose, sequential group study. Each subject participated in only 1 treatment period. The primary objective was to determine the safety of single intramuscular (IM) injections of NAVX 010 in healthy subjects. The secondary objective was to determine the single dose pharmacokinetics (PK) of Gonyautoxin 2 (GTX 2) and Gonyautoxin 3 (GTX 3) following IM administration of NAVX 010 in healthy subjects. Thirty subjects were studied in 5 groups (Groups A to E); each group consisted of 6 subjects, of which 4 subjects received the Investigational Medicinal Product and 2 subjects received placebo. All subjects completed the study and data for all subjects were included in the safety analyses. A total of 20 subjects received NAVX-010 and were included in the PK population and subsequent PK analysis.

Detailed description

This was a double-blind, placebo-controlled, randomized, single ascending dose, sequential group study. Each subject participated in only 1 treatment period. The primary objective was to determine the safety of single intramuscular (IM) injections of NAVX-010 in healthy subjects. The secondary objective was to determine the single dose pharmacokinetics (PK) of Gonyautoxin 2 (GTX 2) and Gonyautoxin 3 (GTX 3) following IM administration of NAVX-010 in healthy subjects. Thirty subjects were studied in 5 groups (Groups A to E); each group consisted of 6 subjects, of which 4 subjects received the Investigational Medicinal Product (IMP; NAVX-010) and 2 subjects received placebo. All subjects completed the study and data for all subjects were included in the safety analyses. A total of 20 subjects received NAVX-010 and were included in the PK population and subsequent PK analysis. This study comprised healthy male subjects of any ethnic origin, aged between 18 and 45 years, inclusive, and with a body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive. Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Doses were administered as IM injections into the deltoid muscle in the fasted state. The IMP was supplied in glass vials containing 1.2 mL solution at a total GTX 2 and GTX 3 concentration of 42 mcg/mL (at a relative epimer ratio of 62% GTX 2:38% GTX 3). Placebo was of identical appearance to the IMP, and was administered into the deltoid muscle in the fasted state. Single IM injections were administered in each group. Blood and urine samples were collected for the analysis of plasma and urinary concentrations of GTX 2 and GTX 3, and the following PK parameters for GTX 2 and GTX 3 were calculated: area under the concentration-time curve (AUC) from time 0 up to the time of last quantifiable plasma concentration (AUC0 t), AUC from time 0 to 24 hours postdose (AUC0-24), AUC from time 0 extrapolated to infinity (AUC0 ∞), percentage of AUC that is due to extrapolation from the time of last quantifiable concentration to infinity (%AUCextrap), maximum observed plasma concentration (Cmax), time of the maximum observed plasma concentration (tmax), time of last quantifiable plasma concentration (tlast), time before the start of absorption (tlag), apparent plasma terminal elimination half life (t½), apparent total plasma clearance (CL/F), apparent volume of distribution during the terminal elimination phase (Vz/F), amount of drug excreted in urine (Ae), percentage of dose excreted in urine (Fe), and renal clearance (CLR). Safety evaluations included adverse events (AEs), vital signs, 12 lead electrocardiogram (ECG), telemetry, clinical laboratory evaluations, physical examination, and clinical study questionnaires.

Conditions

• Safety

Interventions

Type	Name	Description
DRUG	NAVX-010	Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Four patients per active group. Each subject participated in only 1 treatment period.
DRUG	Placebo	There were two Placebos per group.

Timeline

• Start date: 2015-05-14
• Primary completion: 2015-09-02
• Completion: 2015-09-02
• First posted: 2018-08-31
• Last updated: 2018-08-31

Regulatory

• FDA-regulated drug study